

Efrem Gómez Jabalera, MD, FEBVS, is a vascular surgeon who performs his clinical practice in the Hospital Nostra Senyora de Meritxell, Andorra; and in Clinica Sagrada Familia, Barcelona, Spain.

Dr. Gómez Jabalera, Efrem; was received his MD from the University of Lleida in 2010, completed the internship in Angiology and Vascular Surgery at Hospital Santa Creu i Sant, Barcelona, Spain (2011 – 2016), achieved the FEBVS in 2018 and during the latter 3 years he has been doing guards in Hospital Clínic de Barcelona. He is in his last year for the defence of his PhD thesis in Clinical application of 2D perfusion angiography in the treatment of critical limb ischemia, working together with the Philips medical scientific Team. This project has been conducted out of a part-time fellowship during 2 years performed in Policlinico Abano Terme, Padova, Italy. Therefore, his current scientific focus and field of expertise is on the diagnosis, classification and management of the critical limb threatening ischemia.

He is member of the following scientific societies: Societat Catalana d'Angiologia i Cirurgia Vascular i Endovascular, Sociedad Española de Angiología y Cirugía Vascular, Sociedad Española de Arterioesclerosis and the Working Group on Aorta & Peripheral Vascular Diseases of the European Society of Cardiology. He has assisted in several live cases for LINC and CLIC courses and in 8 oral presentations for international symposia for the last 3 years.

---

## References of the author:

1. Use of flow-diverter stents in visceral aneurisms (Utilización de stents direccionadores de flujo en aneurismas viscerales). Gómez Jabalera, E.; Dilmé Muñoz, J.; Villalba Ailón, J.; Soto Carricas, B. ; Escudero JR. *Angiología*, 2015; 67:56-7 DOI: 10.1016/j.angio.2013.10.004. CiteScore 2017: 0.08
2. Clinical factors that influence in the pre-test diagnostic probability of deep vein thrombosis in outpatients (Factores clínicos que influyen en la probabilidad diagnóstica pretest de trombosis venosa profunda en pacientes ambulatorios.) Eva Fuentes Camps, J.L. del Val, S. Bellmunt, S. Hmimina, E Gómez Jabalera, M.A. Muñoz Pérez. *Angiología*, 2015;67:373-9 DOI: 10.1016 / j.angio2015.03.003. CiteScore 2017: 0.08
3. Cost-effectiveness of the deep vein thrombosis diagnosis process in primary care [Estudio del coste efectividad del proceso diagnóstico de la Trombosis venosa profunda]. Eva Fuentes Camps, José Luís del Val García, Sergi Bellmunt Montoya, Sara Hmimina Hmimina, Efren Gómez Jabalera; Miguel Ángel Muñoz Pérez; Aten Primaria. 2016 Apr;48(4):251-7 DOI: 10.1016/j.aprim.2015.05.006. Impact factor: 0.953
4. Targeting the molecular mechanisms of ischemic damage: Protective effects of alpha-crystallin-B. Judit Cubedo, PhD; Gemma Vilahur, PhD; Laura Casani, PhD; Guiomar Mendieta, MD; Efrem Gomez-Jabalera, MD; Oriol Juan-Babot, MD, PhD; Teresa Padro, PhD; Lina Badimon PhD. *International Journal of Cardiology* 2016 Jul 15; 215:406-16 DOI: 10.1016/j.ijcard.2016.04.072. Impact factor: 4.036

5. Age adjusted D-dimer for the diagnosis of deep vein thrombosis. Gomez-Jabalera, E.; Bellmunt, S.; Fuentes, E.; Escudero, J. *Phlebology*. 2017 Jan 1:268355517718762 DOI: 10.1177/0268355517718762. Impact factor: 1.413.  
Recognized with Alberto Masegosa award (SEACV).
6. Drug-coated balloon angioplasty for the management of recurring infrapopliteal disease in diabetic patients with critical limb ischemia. Palena LM, Diaz-Sandoval LJ, Gómez Jabalera E, Peypoch Perez O, Sultato E, Brigato C, Brocco E, Manzi M. *Cardiovasc Revasc Med*. 2017 Jun 20 DOI: 10.1016/j.carrev.2017.06.006. Impact factor: 1.39
7. An European Perspective: Valued Care and the potential for CTO Credentialing. Luis Mariano Palena, Efram Gomez Jabalera, Marco Manzi. *Endovascular Today*, September 2017 Vol. 16 no9
8. Anterolateral retrograde access to the distal popliteal artery and to the tibioperoneal trunk for recanalization of femoropopliteal chronic total occlusions. Silvestro M, Palena LM, Manzi M, Gómez-Jabalera E, Vishwanath D, Casini A, Ferraresi R. *Journal of Vascular Surgery*. 2018 Aug 17. DOI: 10.1016/j.jvs.2018.05.231. Impact factor: 3.294